What are the adequacy criteria in The Paris System for Reporting Urinary Cytology (TSRUC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The adequacy criteria in The Paris System for Reporting Urinary Cytology require at least 20-30 well-visualized urothelial cells for a specimen to be considered adequate.

Key Points

  • Specimens with fewer cells can still be evaluated but should be labeled as "Adequacy Limited" with an explanation of the limitation 1.
  • Specimens are considered "Unsatisfactory" when they contain obscuring elements like blood, lubricant, or inflammation that prevent proper assessment of urothelial cells, or when there are technical issues like poor fixation or staining.
  • The system acknowledges that cellularity requirements may be lower for instrumented specimens (like catheterized urine) compared to voided urine samples.
  • These criteria were established to standardize reporting and ensure reliable cytologic evaluation, as inadequate specimens can lead to false-negative results and missed diagnoses of urothelial carcinoma 1.

Important Considerations

  • Proper specimen collection, handling, and processing are essential to meet these adequacy standards.
  • The Paris System should be used for reporting urinary cytology, as recommended by the European Society for Medical Oncology (ESMO) 1.
  • Urine cytology can facilitate the diagnosis of high-grade urothelial carcinoma but cannot be used as the primary method of histological diagnosis 1.

From the Research

Adequacy Criteria in the Paris System

The Paris System for Reporting Urinary Cytology does not explicitly outline specific adequacy criteria in the provided studies. However, the system focuses on reducing unnecessary indeterminate diagnoses while maintaining its performance in identifying high-grade urothelial carcinoma 2.

Diagnostic Categories

The Paris System comprises seven diagnostic categories:

  • Nondiagnostic
  • Negative for high-grade urothelial carcinoma (NHGUC)
  • Atypical urothelial cells (AUC)
  • Suspicious for high-grade urothelial carcinoma (SHGUC)
  • High-grade urothelial carcinoma (HGUC)
  • Low-grade urothelial neoplasm (LGUN)
  • Other malignancies 3

Risk of High-Grade Malignancy

Each category is linked with a specific risk of high-grade malignancy (ROHM), guiding clinical management:

  • Nondiagnostic: 17.70% ROHM
  • NHGUC: 13.04% ROHM
  • AUC: 38.65% ROHM
  • SHGUC: 76.89% ROHM
  • HGUC and other malignancies: 91.79% ROHM 3

Application of the Paris System

The system has been applied to various studies, including those focusing on upper tract urothelial carcinoma 4 and the evaluation of urine cytology specimens using artificial intelligence 5. However, the adequacy criteria are not explicitly mentioned in these studies.

Urine Cytology Findings

Urine cytology findings in patients with biopsy-confirmed urothelial carcinoma in situ with plasmacytoid features have been evaluated according to the Paris System criteria 6. The study found that the features of this specific type of carcinoma are subtle and often do not meet the Paris System criteria for diagnosis as high-grade urothelial carcinoma.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A review of the Paris system for reporting urinary cytology.

Cytopathology : official journal of the British Society for Clinical Cytology, 2016

Research

The Paris System for Reporting Urinary Cytology: A Meta-Analysis.

Journal of personalized medicine, 2022

Research

A review of urinary cytology in the setting of upper tract urothelial carcinoma.

Journal of the American Society of Cytopathology, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.